Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine

Area of Science:

• Pediatric Infectious Diseases
• Vaccinology
• Immunology

Background:

• Haemophilus influenzae type b (Hib) infections pose a significant risk to young children.
• The development of a capsular polysaccharide vaccine aimed to prevent Hib disease.
• Early vaccination strategies required long-term efficacy and safety evaluation.

Purpose of the Study:

• To assess the long-term protective efficacy of the Hib capsular polysaccharide vaccine.
• To determine the optimal age for effective immunization with the Hib vaccine.
• To analyze the epidemiology of bacteremic Hib infections in children.

Main Methods:

• A long-term follow-up study of approximately 50,000 children vaccinated with the Hib capsular polysaccharide vaccine.
• Analysis of paired serum samples from 514 vaccinated children to assess immunization effectiveness.
• Retrospective analysis of 956 bacteremic H. influenzae infections over five years in Finland.

Main Results:

• The Hib vaccine demonstrated good protective efficacy in children vaccinated at 18 months or older.
• Effective immunization was achieved in children aged 16-20 months and older.
• No adverse effects were reported in the vaccinated cohort.
• Hib infections predominantly occurred in children under 10 years (94%), with 60% of cases in the 1.5 to 9-year age group.

Conclusions:

• The Hib capsular polysaccharide vaccine is safe and effective when administered at 18 months or older.
• Vaccination at 16-20 months of age is crucial for effective immunization.
• A significant proportion of preventable Hib infections occur in children between 1.5 and 9 years of age.